Could a constipation drug help keep colorectal cancer at bay?
NCT ID NCT07405736
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding lubiprostone, a drug usually used for constipation, to standard maintenance therapy can delay cancer recurrence in adults with colorectal cancer that has spread to the lining of the abdomen. About 124 participants who have had surgery will be randomly assigned to receive either maintenance therapy alone or with lubiprostone. The study aims to see if the combination improves progression-free survival at one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lubiprostone
What this could lead to
If it works, this could point toward a new way to delay cancer recurrence in patients with peritoneal metastatic colorectal cancer.
What could go wrong
This is an early phase II trial with only 124 participants, so results may not apply broadly. Lubiprostone is typically used for constipation, and its long-term safety for cancer patients is still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••